1. Home
  2. BGX vs GNLX Comparison

BGX vs GNLX Comparison

Compare BGX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$10.92

Market Cap

135.2M

Sector

Finance

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$3.03

Market Cap

113.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGX
GNLX
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.2M
113.6M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
BGX
GNLX
Price
$10.92
$3.03
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
58.7K
160.7K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9.47
EPS
N/A
N/A
Revenue
N/A
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.38
$2.29
52 Week High
$12.65
$8.54

Technical Indicators

Market Signals
Indicator
BGX
GNLX
Relative Strength Index (RSI) 53.24 58.09
Support Level $10.76 $3.03
Resistance Level $10.97 $3.25
Average True Range (ATR) 0.07 0.19
MACD 0.00 0.00
Stochastic Oscillator 83.67 58.82

Price Performance

Historical Comparison
BGX
GNLX

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: